IL5 and bronchitis: In terms of effect size, benralizumab also showed higher odds for bronchitis and pneumonia in comparison to mepolizumab and reslizumab (OR = 0.76, OR = 0.69, and OR = 0.60 for bronchitis and OR = 0.80, OR = 0.20, and OR = 0.45, respectively, all non-significant).<h4>Conclusion</h4><i>Anti</i>-IL-5 treatments might have different effects on the reporting of some infection events in patients with asthma.